about
Viral hemorrhagic fevers: advancing the level of treatmentThe Risk of Dengue Virus Transmission in Dar es Salaam, Tanzania during an Epidemic Period of 2014.IgG against dengue virus in healthy blood donors, Zanzibar, Tanzania.Improvement of tuberculosis laboratory capacity on Pemba Island, Zanzibar: a health cooperation projectHIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania.Blood kinetics of Ebola virus in survivors and nonsurvivors.Clinical, Virologic, and Epidemiologic Characteristics of Dengue Outbreak, Dar es Salaam, Tanzania, 2014.Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?Efavirenz-based antiretroviral therapy versus nevirapine-including regimens for prevention of mother-to-child transmission of HIV option B plus in resource-limited settings: is there anything missing?Ebola: missed opportunities for Europe-Africa research.Post-caesarean section surgical site infections at a Tanzanian tertiary hospital: a prospective observational study.Accuracy of indirect haemagglutination and western blot assays for the detection of anti-Schistosoma antibodies in non-severe febrile patients in two Tanzanian hospitals.Seroprevalence of dengue infection: a cross-sectional survey in mainland Tanzania and on Pemba Island, Zanzibar.Strengthening tuberculosis diagnosis in a low-resource setting: experience learned in Dodoma, Tanzania.Age and prediction of sustained virological response to hepatitis C virus (HCV) infection treatment based on 28-day decrease in HCV RNA levels.The effect of age on response to therapy with peginterferon alpha plus ribavirin in a cohort of patients with chronic HCV hepatitis including subjects older than 65 yr.Non-randomised Ebola trials--lessons for optimal outbreak research.The prevalence of antibodies to human herpesvirus 8 and hepatitis B virus in patients in two hospitals in Tanzania.The added value of long-lasting preparedness for the management of a patient with Ebola.Criteria for discharge of patients with Ebola virus diseases in high-income countries.Role of hepatitis B virus, hepatitis D virus and other determinants on suppression of hepatitis C viraemia in HIV infected patients with chronic HCV infection: a longitudinal evaluation.Molecular diagnosis and species identification of imported malaria in returning travellers in Italy.Steroid use and clinical sequelae in two survivors of EVD.Local transmission of chikungunya in Rome and the Lazio region, Italy
P50
Q21245298-582E120C-0117-43C2-BA12-2E8AD855E226Q28552906-5E3B4B0E-A07E-481E-A752-52DB6D9E6C42Q30217227-EEA1ED10-53D9-4EF5-B9C9-89AEDFFE25DCQ34406257-D5D408CA-360C-4EA3-87F3-2DB17A1A4A3DQ34993070-76B681EF-931A-47F3-A765-AF3DE5A08A10Q36335941-28480492-F6F5-4375-921F-706ED30A2E8AQ36884942-66A9FB23-3528-4EB9-BC7C-4456552A93CBQ37498564-C89C6628-931A-482B-B8B9-66E988DD9856Q38424462-7EDC9555-5DC1-4B18-8CCA-7481AC5C49B8Q38630880-FCE525C2-0132-4080-AFB2-806B43671D73Q38858286-24BD29A2-BDC5-4924-9885-D2A671D5B05BQ39812833-EE1C2816-D37E-433E-935D-89E8E4FC1160Q40298661-D5AF77FF-9298-4525-A863-EA032E9282D1Q40305743-8B8EEC1B-6C61-45C3-A903-F52DC3E46356Q42247496-E635A94F-2EA0-4E41-9144-39EABFF4F202Q42991672-DCA3F613-AFBB-4A9A-9E32-193AF4EC23C6Q43036906-C9168AE8-8288-49F8-AC2F-DB5821C2896BQ43929126-341E5CFF-B940-4D9E-AA0C-011DC892D08AQ43941682-6A2C297F-9C10-4597-8AC7-FCDB740CDFC1Q44097348-D5654219-0A03-4EEC-860B-22CEA0E46428Q44100989-ED05E92E-76AE-495A-80AD-D7B4A018EB76Q45392641-EE54623D-CDAF-475F-AAC9-540D14CB014EQ47994804-7DA47424-C91E-4E05-8097-86DF3B47A450Q53124957-FC82FE3C-37FF-4DCA-BD74-FCBB9C3A709FQ60941634-01EF70BC-6620-410E-9D0B-D229DEC0D6F6
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesco Vairo
@ast
Francesco Vairo
@en
Francesco Vairo
@es
Francesco Vairo
@nl
Francesco Vairo
@sl
type
label
Francesco Vairo
@ast
Francesco Vairo
@en
Francesco Vairo
@es
Francesco Vairo
@nl
Francesco Vairo
@sl
prefLabel
Francesco Vairo
@ast
Francesco Vairo
@en
Francesco Vairo
@es
Francesco Vairo
@nl
Francesco Vairo
@sl
P1053
M-5676-2013
P106
P1153
36846052400
P21
P31
P3829
P496
0000-0002-8375-7468